<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Cell Infect Microbiol</journal-id><journal-id journal-id-type="iso-abbrev">Front Cell Infect Microbiol</journal-id><journal-id journal-id-type="publisher-id">Front. Cell. Infect. Microbiol.</journal-id><journal-title-group><journal-title>Frontiers in Cellular and Infection Microbiology</journal-title></journal-title-group><issn pub-type="epub">2235-2988</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5056170</article-id><article-id pub-id-type="doi">10.3389/fcimb.2016.00121</article-id><article-categories><subj-group subj-group-type="heading"><subject>Microbiology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title><italic>Helicobacter pylori</italic> Infection Is Associated with Decreased Expression of SLC5A8, a Cancer Suppressor Gene, in Young Children</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Orellana-Manzano</surname><given-names>Andrea</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/360855/overview"/></contrib><contrib contrib-type="author"><name><surname>O'Ryan</surname><given-names>Miguel G.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="author-notes" rid="fn001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/364460/overview"/></contrib><contrib contrib-type="author"><name><surname>Lagomarcino</surname><given-names>Anne J.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>George</surname><given-names>Sergio</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/368011/overview"/></contrib><contrib contrib-type="author"><name><surname>Mu&#x000f1;oz</surname><given-names>Mindy S.</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mamani</surname><given-names>Nora</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Serrano</surname><given-names>Carolina A.</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Harris</surname><given-names>Paul R.</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ramilo</surname><given-names>Octavio</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mej&#x000ed;as</surname><given-names>Asunci&#x000f3;n</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Torres</surname><given-names>Juan P.</given-names></name><xref ref-type="aff" rid="aff7"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lucero</surname><given-names>Yalda</given-names></name><xref ref-type="aff" rid="aff7"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Quest</surname><given-names>Andrew F. G.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/224403/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Host-Pathogen Interaction Laboratory, Microbiology and Mycology Program, Faculty of Medicine, University of Chile</institution><country>Santiago, Chile</country></aff><aff id="aff2"><sup>2</sup><institution>Center for Molecular Studies of the Cell (CEMC), Faculty of Medicine, University of Chile</institution><country>Santiago, Chile</country></aff><aff id="aff3"><sup>3</sup><institution>Advanced Center for Chronic Diseases (ACCDiS), Faculty of Medicine, University of Chile</institution><country>Santiago, Chile</country></aff><aff id="aff4"><sup>4</sup><institution>Computational Systems Biology Laboratory, Faculty of Pharmaceutical Sciences, University of S&#x000e3;o Paulo</institution><country>S&#x000e3;o Paulo, Brazil</country></aff><aff id="aff5"><sup>5</sup><institution>Pediatric Gastroenterology and Nutrition Department, School of Medicine, Pontifical Catholic University of Chile</institution><country>Santiago, Chile</country></aff><aff id="aff6"><sup>6</sup><institution>Center for Vaccines and Immunity, The Research Institute at Nationwide Children's Hospital</institution><country>Columbus, OH, USA</country></aff><aff id="aff7"><sup>7</sup><institution>Department of Pediatrics and Pediatric Surgery (Eastern Campus), Faculty of Medicine, Luis Calvo Mackenna Hospital, University of Chile</institution><country>Santiago, Chile</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Jean-Pierre Gorvel, Centre National de la Recherche Scientifique, France</p></fn><fn fn-type="edited-by"><p>Reviewed by: Jo&#x000e3;o Paulo Gomes, National Institute of Health, Portugal; Alexandra Papadopoulou, Agia Sophia Children's Hospital, University of Athens, Greece</p></fn><corresp id="fn001">*Correspondence: Miguel G. O'Ryan <email xlink:type="simple">moryan@med.uchile.cl</email></corresp></author-notes><pub-date pub-type="epub"><day>10</day><month>10</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>6</volume><elocation-id>121</elocation-id><history><date date-type="received"><day>12</day><month>7</month><year>2016</year></date><date date-type="accepted"><day>21</day><month>9</month><year>2016</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2016 Orellana-Manzano, O'Ryan, Lagomarcino, George, Mu&#x000f1;oz, Mamani, Serrano, Harris, Ramilo, Mej&#x000ed;as, Torres, Lucero and Quest.</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Orellana-Manzano, O'Ryan, Lagomarcino, George, Mu&#x000f1;oz, Mamani, Serrano, Harris, Ramilo, Mej&#x000ed;as, Torres, Lucero and Quest</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p><bold>Background:</bold>
<italic>Helicobacter pylori</italic> infects half of the world's population and causes gastric cancer in a subset of infected adults. Previous blood microarray findings showed that apparently healthy children, persistently infected with <italic>H. pylori</italic> have differential gene expression compared to age-matched, non-infected children. SLC5A8, a cancer suppressor gene with decreased expression among infected children, was chosen for further study based on bioinformatics analysis.</p><p><bold>Methods:</bold> A pilot study was conducted using specific qRT-PCR amplification of SLC5A8 in blood samples from <italic>H. pylori</italic> infected and non-infected children, followed by a larger, blinded, case-control study. We then analyzed gastric tissue from <italic>H. pylori</italic> infected and non-infected children undergoing endoscopy for clinical purposes.</p><p><bold>Results:</bold> Demographics, clinical findings, and family history were similar between groups. SLC5A8 expression was decreased in infected vs. non-infected children in blood, 0.12 (IQR: 0&#x02013;0.89) vs. 1.86 (IQR: 0&#x02013;8.94, <italic>P</italic> = 0.002), and in gastric tissue, 0.08 (IQR: 0.04&#x02013;0.15) vs. 1.88 (IQR: 0.55&#x02013;2.56; <italic>P</italic> = 0.001). Children who were both stool positive and seropositive for <italic>H. pylori</italic> had the lowest SLC5A8 expression levels.</p><p><bold>Conclusions:</bold>
<italic>H. pylori</italic> infection is associated with suppression of SCL5A8, a cancer suppressor gene, in both blood and tissue samples from young children.</p><p><bold>Key Points:</bold> Young children, persistently infected with <italic>Helicobacter pylori</italic> show decreased expression of SLC5A8 mRNA in both blood and tissue samples as compared to non-infected children.</p></abstract><kwd-group><kwd><italic>Helicobacter pylori</italic></kwd><kwd>persistent infection</kwd><kwd>children</kwd><kwd>SLC5A8</kwd><kwd>cancer suppressor gene</kwd><kwd>qPCR detection</kwd></kwd-group><funding-group><award-group><funding-source id="cn001">Fondo Nacional de Desarrollo Cient&#x000ed;fico y Tecnol&#x000f3;gico<named-content content-type="fundref-id">10.13039/501100002850</named-content></funding-source><award-id rid="cn001">1061079</award-id><award-id rid="cn001">1100514</award-id><award-id rid="cn001">1130387</award-id><award-id rid="cn001">11140232</award-id></award-group><award-group><funding-source id="cn002">Comisi&#x000f3;n Nacional de Investigaci&#x000f3;n Cient&#x000ed;fica y Tecnol&#x000f3;gica<named-content content-type="fundref-id">10.13039/501100002848</named-content></funding-source><award-id rid="cn002">21140520</award-id></award-group><award-group><funding-source id="cn003">Fondo de Financiamiento de Centros de Investigaci&#x000f3;n en &#x000c1;reas Prioritarias</funding-source><award-id rid="cn003">15130011</award-id></award-group><award-group><funding-source id="cn004">Secretar&#x000ed;a de Educaci&#x000f3;n Superior, Ciencia, Tecnolog&#x000ed;a e Innovaci&#x000f3;n<named-content content-type="fundref-id">10.13039/501100004299</named-content></funding-source></award-group></funding-group><counts><fig-count count="4"/><table-count count="4"/><equation-count count="0"/><ref-count count="37"/><page-count count="9"/><word-count count="6264"/></counts></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p><italic>Helicobacter pylori</italic> (<italic>H. pylori</italic>) is a Gram-negative bacillus that infects half of the world's population and causes gastric cancer in a subset of infected adults (Malaty, <xref rid="B19" ref-type="bibr">2007</xref>). According to a &#x0201c;National Health Survey&#x0201d; performed in Chile in 2003, the <italic>H. pylori</italic> seroprevalence rate in adults 17 years of age and older is 73% (Minsal, <xref rid="B21" ref-type="bibr">2004</xref>).</p><p><italic>H. pylori</italic> can be acquired during the first year of life, especially in populations living in lower socioeconomic environments, although information on childhood infection is scarce (Daugule and Rowland, <xref rid="B4" ref-type="bibr">2008</xref>; Jaime et al., <xref rid="B14" ref-type="bibr">2013</xref>; O'Ryan et al., <xref rid="B24" ref-type="bibr">2013</xref>, <xref rid="B23" ref-type="bibr">2015</xref>). We previously reported that 20&#x02013;25% of children under 5 years of age from a semi-rural area of Chile are persistently infected with <italic>H. pylori</italic>, based on prolonged detection of antigen in stools (O'Ryan et al., <xref rid="B24" ref-type="bibr">2013</xref>, <xref rid="B23" ref-type="bibr">2015</xref>). Most persistently infected children do not present signs or symptoms during early childhood; to date, only 2/50 children followed up until a median age of 5 years and 10 months (range: 2 years 6month&#x02013;8 years10 momth) have presented abdominal complaints. Comparing whole blood microarray data from infected children with non-infected, age-matched controls we identified differential expression of nearly 100 genes (O'Ryan et al., <xref rid="B23" ref-type="bibr">2015</xref>). Based on bioinformatics analysis and gene characterization, and specifically because of its association with cancer, we targeted the gene SLC5A8 for further study.</p><p>SLC5A8 is a monocarboxylate transporter located in several tissues and organs, including the gastrointestinal tract (Zhang et al., <xref rid="B37" ref-type="bibr">2010</xref>; Brim et al., <xref rid="B1" ref-type="bibr">2011</xref>). This gene encodes a transmembrane protein that facilitates entrance of butyrate, propionate, and other short-chain fatty acids into normal cells. Incorporation of butyrate into tumor cells of both gastric and colon cancers favors tumor suppression by inhibiting inflammation, promoting cell differentiation, stimulating cell cycle arrest, and inducing apoptosis (Elangovan et al., <xref rid="B6" ref-type="bibr">2013</xref>; Park et al., <xref rid="B26" ref-type="bibr">2013</xref>; Gurav et al., <xref rid="B11" ref-type="bibr">2015</xref>). Ueno et al. demonstrated that SLC5A8 was downregulated in adults with gastric cancer (Ueno et al., <xref rid="B35" ref-type="bibr">2004</xref>) and was silenced in ~60% of individuals with colorectal cancer (Keenan and Frizelle, <xref rid="B15" ref-type="bibr">2014</xref>), and others have confirmed that it is downregulated in several cancer types, including stomach (Ueno et al., <xref rid="B35" ref-type="bibr">2004</xref>; Ganapathy et al., <xref rid="B10" ref-type="bibr">2008</xref>), colon (Li et al., <xref rid="B18" ref-type="bibr">2003</xref>; Miyauchi et al., <xref rid="B22" ref-type="bibr">2004</xref>; Thangaraju et al., <xref rid="B32" ref-type="bibr">2008</xref>), thyroid (Ganapathy et al., <xref rid="B9" ref-type="bibr">2005</xref>; Porra et al., <xref rid="B27" ref-type="bibr">2005</xref>; Schagdarsurengin et al., <xref rid="B31" ref-type="bibr">2006</xref>), and breast (Thangaraju et al., <xref rid="B33" ref-type="bibr">2006</xref>, <xref rid="B34" ref-type="bibr">2009</xref>; Coothankandaswamy et al., <xref rid="B3" ref-type="bibr">2013</xref>; Elangovan et al., <xref rid="B6" ref-type="bibr">2013</xref>). Silencing has also been observed in earlier stages of cancer, including, colonic adenomas and colonic-crypts (Li et al., <xref rid="B18" ref-type="bibr">2003</xref>). Although decreased SLC5A8 expression has been reported among individuals with gastric cancer, it has not been directly associated with <italic>H. pylori</italic> infection in adults or in children with symptomatic or asymptomatic infection.</p><p>The aim of this study was to confirm and expand on our blood microarray findings by determining if SLC5A8 expression levels are decreased in asymptomatic as well as symptomatic children infected with <italic>H. pylori</italic> compared to non-infected children.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec><title>Bioinformatics selection of the gene SLC5A8</title><p>We previously performed microarray analysis on blood samples from persistently, transiently and non-<italic>H. pylori</italic> infected children (O'Ryan et al., <xref rid="B23" ref-type="bibr">2015</xref>). Further analysis of persistent compared to non-infected children identified 97 differentially expressed genes (Supplementary Table <xref ref-type="supplementary-material" rid="SM1">2</xref>). These 97 genes were then classified by biological function using DAVID tools and by function and associated disease using the IPA&#x000ae; system (Huang et al., <xref rid="B13" ref-type="bibr">2009</xref>; Kr&#x000e4;mer et al., <xref rid="B17" ref-type="bibr">2014</xref>).</p><p>Based on analysis with DAVID tools, we selected 20 genes belonging to the three clusters with the highest scores (Figure <xref ref-type="fig" rid="F1">1</xref>, Supplementary Tables <xref ref-type="supplementary-material" rid="SM1">3, 4</xref>). Additionally, 26 genes from one cluster associated with cancer were selected based on analysis with the IPA&#x000ae; system (Supplementary Table <xref ref-type="supplementary-material" rid="SM1">5</xref>). Ten of these 36 genes overlapped (Figure <xref ref-type="fig" rid="F1">1B</xref>). A literature review focusing on cancer and <italic>H. pylori</italic> was performed for these 10 genes (see Supplementary Material for more details). This review indicated that eight genes are associated with cancer progression.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Identification of the target gene, SLC5A8, using different bioinformatics tools. (A)</bold> Scheme describing the bioinformatics pathway used to select our target gene; <bold>(B)</bold> Venn diagram of those genes identified by both Ingenuity and DAVID tools.</p></caption><graphic xlink:href="fcimb-06-00121-g0001"/></fig><p>SLC5A8 was selected because it was recently identified as a cancer suppressor gene and because previous studies related downregulation of this gene to the progression of various types of cancer, including gastric (Ueno et al., <xref rid="B35" ref-type="bibr">2004</xref>), colonic (Li et al., <xref rid="B18" ref-type="bibr">2003</xref>; Thangaraju et al., <xref rid="B32" ref-type="bibr">2008</xref>; Brim et al., <xref rid="B1" ref-type="bibr">2011</xref>), thyroid (Porra et al., <xref rid="B27" ref-type="bibr">2005</xref>), and breast cancers (Foglietta et al., <xref rid="B8" ref-type="bibr">2014</xref>).</p></sec><sec><title>Study design, recruitment, and <italic>H. pylori</italic> detection</title><p>Recruitment, blood sample, and data collection for the healthy child cohort as well as informed consent were approved by the Comit&#x000e9; de Etica de Investigaci&#x000f3;n, Servicio de Salud Metropolitano Norte and by the Comit&#x000e9; de Etica, Universidad de Chile. Recruitment, tissue sample and data collection for children undergoing endoscopy was approved by the Comit&#x000e9; de Etica de Investigaci&#x000f3;n, Pontificia Universidad Cat&#x000f3;lica (Project #PUC12-236). For the healthy child cohort, children were categorized as having a persistent <italic>H. pylori</italic> infection if they had three or more stool samples (obtained every 3&#x02013;4 months) consecutively positive for <italic>H. pylori</italic> by ELISA over several years of follow up (median age of follow-up: 5 years 10 months, range: 2 years 6 month&#x02013;8 years 10 month) (O'Ryan et al., <xref rid="B24" ref-type="bibr">2013</xref>, <xref rid="B23" ref-type="bibr">2015</xref>). Non-infected children were those whose stool samples were never positive for <italic>H. pylori</italic> by ELISA during the follow-up period.</p><p><italic>Blood samples H. pylori</italic> persistently infected and non-infected children were matched by age, gender, and city. One milliliter of blood was obtained from all children by venipuncture, stored in Tempus blood RNA tubes (Thermo Fisher Scientific N&#x000b0;4342792) and transported to the laboratory following the appropriate cold chain protocols for gene expression assays.</p><p>We analyzed blood samples from children in our ongoing child cohorts, all of whom had been previously consented for a pilot study and a larger case-control study. For the pilot study, we randomly selected 16 blood samples from children under 5 years of age that had been previously analyzed by microarray (O'Ryan et al., <xref rid="B23" ref-type="bibr">2015</xref>). For the blind, case-control study, 50 persistent and 44 non-infected children were selected (see Supplementary Material and Figure <xref ref-type="fig" rid="F2">2</xref>). The laboratory staff was blind to <italic>H. pylori</italic> infection status. <italic>H. pylori</italic> was detected by stool ELISA (O'Ryan et al., <xref rid="B24" ref-type="bibr">2013</xref>, <xref rid="B23" ref-type="bibr">2015</xref>) using the commercial ELISA Premier Platinum HpSA monoclonal antibody kit (Meridian Bioscience, Ohio, USA). All samples positive for 16S rRNA were tested for the presence of <italic>CagA</italic> by qRT-PCR, as described in the Supplementary Material.</p><fig id="F2" position="float"><label>Figure 2</label><caption><p><bold>Flow diagram of study patients</bold>. The asymptomatic cohort is comprised of children under 5 years old, and the symptomatic cohort children under 12 years old. Some children from the asymptomatic cohort were included in both the bioinformatics analysis and the pilot/blinded-study, but all these samples were reprocessed within their respective studies.</p></caption><graphic xlink:href="fcimb-06-00121-g0002"/></fig><p><italic>Stool samples</italic> were obtained every 3 or 4 months and transported, following appropriate cold chain protocols, to our laboratory for detection of <italic>H. pylori</italic> antigen by ELISA. Stool samples were stored at &#x02212;80&#x000b0;C. Bacterial DNA was extracted using the QIAamp DNA stool kit (Qiagen, Hilden, Germany) following manufacturer's instructions, with an additional bead-beating step to increase the yield of purified DNA. Detection of <italic>16S</italic> rRNA and <italic>cagA</italic> was performed using previously described primers (O'Ryan et al., <xref rid="B23" ref-type="bibr">2015</xref>) (Supplementary Table <xref ref-type="supplementary-material" rid="SM1">1</xref>). Amplification was performed in a reaction volume of 20 &#x003bc;L with Fast EvaGreen dye qPCR master mix (Biotium, Hayward. CA) with 4 &#x003bc;l of total purified DNA from each stool sample. The PCR reaction was performed using a STEP ONE thermocycler&#x000ae; (Applied Biosystems, Foster City, CA). A three-step PCR was used followed by melting curve analysis. Strain ATCC 43504 was used as the positive control. Amplification of total bacterial 16S rRNA gene was performed using an in-house PCR, in order to identify samples with possible PCR inhibitors. Each sample was analyzed in duplicate within each qRT-PCR reaction.</p></sec><sec><title><italic>H. pylori</italic> detection in gastric tissue</title><p>Gastric samples were analyzed from 24 patients, 5&#x02013;12 years of age, who underwent endoscopy due to symptoms such as abdominal pain, vomiting, and/or diarrhea. All patients answered a clinical questionnaire that included age, gender, and relevant clinical data. Informed consent was obtained from the patient's parents or legal guardians. Upper gastrointestinal endoscopy was performed in the Hospital Cl&#x000ed;nico UC CHRISTUS and stored at &#x02212;80&#x000b0;C in the Department of Pediatric Gastroenterology and Nutrition, School of Medicine, Pontificia Universidad Cat&#x000f3;lica de Chile. Three biopsies were obtained from the gastric antrum, one for Rapid Urease Test (Hepytest&#x000ae;, BiosChile, Santiago, Chile), one for histological staining of <italic>H. pylori</italic> and one for mRNA extraction and SLC5A8 expression analysis. A patient was considered infected with <italic>H. pylori</italic> if both urease and histology staining were positive.</p></sec><sec><title><italic>H. pylori</italic> serology</title><p>A commercial ELISA kit for anti-<italic>H. pylori</italic> antibodies was used to analyze serum samples according to the manufacturer's instructions (Premier&#x000ae; <italic>H. pylori;</italic> Meridian Bioscience, Cincinnati, Ohio, USA), as previously described (O'Ryan et al., <xref rid="B23" ref-type="bibr">2015</xref>).</p></sec><sec><title>SLC5A8 gene expression assay in blood and tissue</title><p>RNA was extracted from blood using the QIAamp RNA Blood Mini Kit (ID: 52304, Qiagen, Hilden, Germany). It was then treated with DNases using the TURBO DNA-Free&#x02122; Kit (AM1907 AMBION, Thermo Fisher Scientific. Oklahoma, USA) and quantified using NanoQuant Take3 equipment. cDNA was obtained using the ImProm-II&#x02122; Reverse Transcription System (ID: A3800, Promega, Madison, Wisconsin, USA).</p><p>Endoscopic biopsies were frozen in liquid nitrogen immediately upon sampling and stored at &#x02212;80&#x000b0;C until analysis. Total RNA was extracted using the RNAeasy kit (Qiagen; Hilden, Germany) and quantified using NanoQuant Take3 equipment. Reverse transcription was performed in a minimum of 1 &#x003bc;g total RNA; integrity was revised in 1% agarose gel using a commercial kit (AffinityScript QPCR cDNA synthesis kit, Agilent Technologies; Santa Clara, California, USA). A mix of DT oligos and random primers was used for the synthesis of cDNA.</p><p>Taqman&#x000ae; probes (Applied Biosystems, Foster City, California, USA) were used for the qPCR gene expression assay. Expression of SLC5A8 was normalized to the housekeeping gene &#x003b2;-actin and expression levels are reported using the 2<sup>&#x00394;CT</sup> quantification method (Rao et al., <xref rid="B28" ref-type="bibr">2013</xref>). qRT-PCR assays were performed in a STEP ONE thermocycler&#x000ae; (Applied Biosystems, Foster City, CA). A gastric tissue sample that expressed SLC5A8 was used as a positive control; non-reverse transcription RNA and water were used as negative controls. All samples were analyzed in three independent experiments; in each experiment we ran the samples in duplicate (in order to obtain one valid value). The average of the values from the three experiments was used for analysis.</p></sec><sec><title>Statistical analysis</title><p>Statistical analysis was performed using R Version 3.0.0 (R Development Core Team, <xref rid="B29" ref-type="bibr">2013</xref>). For categorical variables, groups were compared using the Chi-squared test; the Kruskal&#x02013;Wallis test was used for continuous, non-normal variables. <italic>P</italic>-values &#x02264; 0.05 were considered significant.</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><sec><title>Expression of SLC5A8 is decreased in blood samples from infected compared with non-infected children</title><sec><title>Pilot study</title><p>We performed quantitative reverse transcription PCR (qRT-PCR) for SLC5A8 and &#x003b2;-Actin on blood samples from nine infected and seven non-infected children (for definitions see Supplementary Material). Overall, persistently infected children had lower levels of SLC5A8 mRNA (0.03; IQR 0&#x02013;0.08), compared to non-infected children (3.17; IQR 0.57&#x02013;4.88; <italic>P</italic> = 0.050; Figure <xref ref-type="fig" rid="F3">3A</xref>). Similarly, we compared the median expression of each group observing an approximately 120-fold decrease in expression in infected children compared with non-infected children.</p><fig id="F3" position="float"><label>Figure 3</label><caption><p><bold>SLC5A8 expression is decreased in blood samples from infected compared with non-infected children</bold>. All four panels show a dot plot overlying a boxplot (showing the median and IQR; points outside the whisker lines are considered outliers, as specified by Turkey's Test). Summary statistics are shown below each panel. <bold>(A)</bold> mRNA SLC5A8 expression is significantly decreased in blood samples from <italic>H. pylori</italic> infected compared to non-infected children in the pilot study (Kruskal&#x02013;Wallis test, <italic>P</italic> = 0.050). <bold>(B)</bold> In a blinded case-control study of SLC5A8 expression in blood samples, expression levels are significantly decreased in infected compared to non-infected children (Kruskal&#x02013;Wallis test, <italic>P</italic> = 0.002). Four outliers were not shown for space (infected: 42; non-infected: 72, 212, 379). <bold>(C)</bold> mRNA SLC5A8 expression is decreased in infected and <italic>H. pylori</italic> seropositive children vs. non-infected, seronegative children (Kruskal&#x02013;Wallis test, <italic>P</italic> = 0.002). One outlier was not shown for space (non-infected/seronegative: 378.51) <bold>(D)</bold> mRNA SLC5A8 expression does not differ (based on the Kruskal&#x02013;Wallis test) between CagA positive and negative children. One outlier was not shown for space (CagA positive: 42.03).</p></caption><graphic xlink:href="fcimb-06-00121-g0003"/></fig></sec><sec><title>Blinded case-control study of SLC5A8 expression in blood samples</title><p>We blindly analyzed 94 blood samples, 50 from <italic>H. pylori</italic> infected and 44 from non-infected children. There were no statistically significant differences between infected and non-infected children in demographic variables, family and past medical history, medication use and gastric symptomatology (Table <xref ref-type="table" rid="T1">1</xref>). SLC5A8 expression was decreased in the infected (0.12; IQR 0&#x02013;0.89) compared to the non-infected group (1.86; IQR 0&#x02013;8.94; <italic>P</italic> = 0.002; Figure <xref ref-type="fig" rid="F3">3B</xref>). Similarly, a significant difference was observed when we categorized expression levels using a cutoff of &#x0003c; 2 (&#x0003c; 2 and &#x0003e;1) and (&#x02264; 1) (Table <xref ref-type="table" rid="T2">2</xref>; <italic>P</italic> = 0.008). The comparison of the median expression levels of each group revealed a 5-fold decrease in infected vs. non-infected children.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p><bold>Demographic, clinical, and family characteristics of children enrolled in the case-control study according to <italic>H. pylori</italic> status</bold>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" colspan="2" style="border-bottom: thin solid #000000;" rowspan="1"><italic><bold>H. pylori status</bold></italic></th></tr><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1"><bold>Non-infected</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Infected</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Characteristic, <italic>N</italic> (%)<xref ref-type="table-fn" rid="TN1"><sup>A</sup></xref></td><td valign="top" align="center" rowspan="1" colspan="1"><italic>N</italic> = 44</td><td valign="top" align="center" rowspan="1" colspan="1"><italic>N</italic> = 50</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Male</td><td valign="top" align="center" rowspan="1" colspan="1">25 (57)</td><td valign="top" align="center" rowspan="1" colspan="1">29 (58)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Age (months), median (IQR)</td><td valign="top" align="center" rowspan="1" colspan="1">63 (25&#x02013;91)</td><td valign="top" align="center" rowspan="1" colspan="1">63 (24&#x02013;99)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Attended day care prior to age 2</td><td valign="top" align="center" rowspan="1" colspan="1">13 (30)</td><td valign="top" align="center" rowspan="1" colspan="1">16 (32)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Attended day care prior to age 4</td><td valign="top" align="center" rowspan="1" colspan="1">13 (30)</td><td valign="top" align="center" rowspan="1" colspan="1">10 (20)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Treated with Omeprazole</td><td valign="top" align="center" rowspan="1" colspan="1">0/41 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">1/46 (2)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Family history of <italic>H. pylori</italic></td><td valign="top" align="center" rowspan="1" colspan="1">7 (16)</td><td valign="top" align="center" rowspan="1" colspan="1">3 (6)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Family history of gastric cancer</td><td valign="top" align="center" rowspan="1" colspan="1">9 (20)</td><td valign="top" align="center" rowspan="1" colspan="1">6 (12)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Family history of gastric ulcer</td><td valign="top" align="center" rowspan="1" colspan="1">13 (30)</td><td valign="top" align="center" rowspan="1" colspan="1">15 (30)</td></tr></tbody></table><table-wrap-foot><p><italic>None of the listed characteristics were significantly different between the two groups</italic>.</p><fn id="TN1"><label>A</label><p><italic>unless otherwise noted</italic>.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p><bold>Distribution of SLC5A8 expression levels in <italic>H. pylori</italic> infected and non-infected children</bold>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" colspan="3" style="border-bottom: thin solid #000000;" rowspan="1"><bold>Number (%) of subjects with indicated expression level according to <italic>H. pylori</italic> infection status</bold></th></tr></thead><tbody><tr><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"><bold>Non-infected</bold></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>Infected</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Expression level</td><td valign="top" align="center" rowspan="1" colspan="1"><italic>N</italic> = 44</td><td valign="top" align="center" rowspan="1" colspan="1"><italic>N</italic> = 50</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x0003e; 2</td><td valign="top" align="center" rowspan="1" colspan="1">26 (59)</td><td valign="top" align="center" rowspan="1" colspan="1">12 (24)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02264; 2 and &#x0003e;1</td><td valign="top" align="center" rowspan="1" colspan="1">6 (14)</td><td valign="top" align="center" rowspan="1" colspan="1">19 (38)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02264; 1</td><td valign="top" align="center" rowspan="1" colspan="1">12 (27)</td><td valign="top" align="center" rowspan="1" colspan="1">19 (38)</td></tr></tbody></table><table-wrap-foot><p><italic>P = 0.008 by Chi-squared test</italic>.</p></table-wrap-foot></table-wrap><p>It is worth also mentioning that there were samples in which expression levels were not detectable, 12 infected and 4 non-infected children. We decided to include these samples as part of the analysis, assigning them an expression value of 0. However, even when excluding these samples from the analysis the relationship remains significant (non-infected: 2.92, IQR 0.72&#x02013;10.84 vs. infected: 0.44, IQR 0.03&#x02013;2.17: <italic>P</italic> = 0.005).</p><p>In addition to stool antigen detection, we compared mRNA SLC5A8 in a subset of children with differing anti-<italic>H. pylori</italic> serology status. Out of 50 stool ELISA positive children, 40 were seropositive for <italic>H. pylori</italic> (80%), whereas 4/33 (12%) stool ELISA negative children were seropositive (<italic>P</italic> &#x0003c; 0.001; 11 non-infected children do not have serology results available). For <italic>H. pylori</italic> infected seropositive children median SLC5A8 expression levels were 0.04 (IQR: 0&#x02013;0.79) vs. 1.81 (IQR: 0.36&#x02013;8.74) for non-infected seronegative children (<italic>P</italic> = 0.002; Figure <xref ref-type="fig" rid="F3">3C</xref>). A comparison of the median expression levels revealed a 5-fold decrease in infected/seropositive compared to non-infected/seronegative children.</p><p>Real time PCR (qRT-PCR) 16SrRNA amplification was performed on one stool sample per persistent child in order to confirm ELISA positive results; 46/50 samples were confirmed. These samples were then analyzed by qRT-PCR for the <italic>CagA</italic> virulence gene. No significant difference in SLC5A8 expression was observed between <italic>CagA</italic> positive, (<italic>n</italic> = 22, 0.20; IQR: 0&#x02013;0.88) or negative children (<italic>n</italic> = 24, 0.05 IQR: 0&#x02013;1.37; <italic>P</italic> = NS) suggesting the lack of a consistent relationship between SLC5A8 expression and infection with a <italic>CagA</italic> positive or negative <italic>H. pylori</italic> strains (Figure <xref ref-type="fig" rid="F3">3D</xref>).</p></sec></sec><sec><title>SLC5A8 expression is decreased in tissue samples of <italic>H. pylori</italic> infected compared to non-infected children</title><sec><title>Blinded case-control study of SLC5A8 expression in gastric biopsies of H. pylori infected and non-infected children</title><p>We analyzed gastric tissue from 12 <italic>H. pylori</italic> infected (as determined by positive rapid urease test and histology staining) and 12 non-infected children under 10 years of age who underwent endoscopy due to abdominal complaints. There were no significant differences in demographic characteristics or gastric symptomatology between groups (Table <xref ref-type="table" rid="T3">3</xref>). SLC5A8 mRNA was significantly lower in infected (0.08; IQR: 0.04&#x02013;0.15) compared to non-infected children (1.88; IQR: 0.55&#x02013;2.56; <italic>P</italic> = 0.001; Figure <xref ref-type="fig" rid="F4">4</xref>). The difference in the median expression of each group revealed a 24-fold decrease among infected compared to non-infected children.</p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p><bold>Demographic, symptomatology, and gastric biopsy results of infected and non-infected children undergoing endoscopy</bold>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" colspan="2" style="border-bottom: thin solid #000000;" rowspan="1"><bold><italic>H. pylori</italic> status</bold></th><th rowspan="1" colspan="1"/></tr><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1"><bold>Non-infected</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Infected</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold><italic>P</italic>-value</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Characteristic, <italic>N</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1"><italic>N</italic> = 12</td><td valign="top" align="center" rowspan="1" colspan="1"><italic>N</italic> = 12</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Male</td><td valign="top" align="center" rowspan="1" colspan="1">7 (29)</td><td valign="top" align="center" rowspan="1" colspan="1">5 (21)</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Age in years, median (IQR)</td><td valign="top" align="center" rowspan="1" colspan="1">12.5 (5&#x02013;17)</td><td valign="top" align="center" rowspan="1" colspan="1">12 (8&#x02013;14)</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Body Mass Index</td><td valign="top" align="center" rowspan="1" colspan="1">20.1 (16.2&#x02013;23.9)</td><td valign="top" align="center" rowspan="1" colspan="1">21.3 (13.9&#x02013;31.2)</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td></tr><tr><td valign="top" align="left" colspan="4" style="background-color:#bbbdc0" rowspan="1"><bold>SYMPTOM SEVERITY</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">No symptom</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Mild</td><td valign="top" align="center" rowspan="1" colspan="1">4 (33)</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Moderate</td><td valign="top" align="center" rowspan="1" colspan="1">5 (42)</td><td valign="top" align="center" rowspan="1" colspan="1">4 (33)</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Severe</td><td valign="top" align="center" rowspan="1" colspan="1">3 (25)</td><td valign="top" align="center" rowspan="1" colspan="1">6 (50)</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td></tr><tr><td valign="top" align="left" colspan="4" style="background-color:#bbbdc0" rowspan="1"><bold>SYMPTOMS DURATION</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">1 week</td><td valign="top" align="center" rowspan="1" colspan="1">7 (58)</td><td valign="top" align="center" rowspan="1" colspan="1">5 (46)</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">1 month</td><td valign="top" align="center" rowspan="1" colspan="1">3 (25)</td><td valign="top" align="center" rowspan="1" colspan="1">4 (36)</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">1 year</td><td valign="top" align="center" rowspan="1" colspan="1">2 (17)</td><td valign="top" align="center" rowspan="1" colspan="1">2 (18)</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td></tr><tr><td valign="top" align="left" colspan="4" style="background-color:#bbbdc0" rowspan="1"><bold>UPPER GI ENDOSCOPY REPORT</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Normal</td><td valign="top" align="center" rowspan="1" colspan="1">5 (42)</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0.016</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Gastropathy</td><td valign="top" align="center" rowspan="1" colspan="1">3 (25)</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0.064</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Nodules</td><td valign="top" align="center" rowspan="1" colspan="1">4 (33)</td><td valign="top" align="center" rowspan="1" colspan="1">12 (100)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td valign="top" align="left" colspan="4" style="background-color:#bbbdc0" rowspan="1"><bold>HISTOLOGY REPORT<xref ref-type="table-fn" rid="TN2"><sup>*</sup></xref></bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Gastritis</italic></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Absence</td><td valign="top" align="center" rowspan="1" colspan="1">6 (55)</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Mild</td><td valign="top" align="center" rowspan="1" colspan="1">5 (45)</td><td valign="top" align="center" rowspan="1" colspan="1">5 (55)</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Moderate</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">4 (45)</td><td valign="top" align="left" rowspan="1" colspan="1">0.011</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Inflammatory activity</italic></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Absence</td><td valign="top" align="center" rowspan="1" colspan="1">11 (100)</td><td valign="top" align="center" rowspan="1" colspan="1">4 (45)</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Presence</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">5 (55)</td><td valign="top" align="left" rowspan="1" colspan="1">0.08</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Lymphoid follicles</italic></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Presence</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">2 (22)</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Absence</td><td valign="top" align="center" rowspan="1" colspan="1">11 (100)</td><td valign="top" align="center" rowspan="1" colspan="1">7 (78)</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Atrophy</italic></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Presence</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Absence</td><td valign="top" align="center" rowspan="1" colspan="1">10 (91)</td><td valign="top" align="center" rowspan="1" colspan="1">9 (100)</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td></tr></tbody></table><table-wrap-foot><fn id="TN2"><label>*</label><p><italic>data available for 20 subjects</italic>.</p></fn></table-wrap-foot></table-wrap><fig id="F4" position="float"><label>Figure 4</label><caption><p><bold>SLC5A8 expression is decreased in <italic>H. pylori</italic> infected compared to non-infected children in gastric tissue samples (Kruskal&#x02013;Wallis test, <italic>P</italic> = 0.001)</bold>. The plot is composed of a dot plot overlying a boxplot (showing the median and IQR; points outside the whisker lines are considered outliers, as specified by Turkey's Test); summary statistics are shown beneath the graph.</p></caption><graphic xlink:href="fcimb-06-00121-g0004"/></fig><p>Histological information was available in 20 of the 24 children with tissue samples. A pathologist determined the degree of gastric damage, inflammatory activity, presence of lymphoid follicles, and the presence or absence of gastric atrophy (Supplementary Table <xref ref-type="supplementary-material" rid="SM1">6</xref>). The higher the score, the greater the gastric damage, and inflammatory processes; the score is based on a scale of 0 (no damage), 1 (mild damage), 2 (moderate damage) to 3 (severe damage). Symptoms, such as vomiting, recurrent abdominal pain, were also scored by the treating physicians as low, moderate and severe. Information on symptom duration was grossly classified as occurring only during the previous week, for at least a month, or for at least 1 year.</p><p>We analyzed each indicator of gastric damage and symptomatology (inflammatory activity, gastritis, lymphoid follicles, atrophy, symptoms and duration of symptoms). More severe gastritis (<italic>P</italic> = 0.019), and presence of lymphoid follicles (<italic>P</italic> = 0.044) were significantly associated with decreased SLC5A8 expression levels (Supplementary Figures <xref ref-type="supplementary-material" rid="SM1">1, 2</xref>). The following variables did not show a significant association with expression levels: Inflammatory activity (<italic>P</italic> = 0.150), atrophy (<italic>P</italic> = 0.603), symptoms (<italic>P</italic> = 0.872) (Supplementary Figures <xref ref-type="supplementary-material" rid="SM1">3&#x02013;5</xref>) and symptom duration (<italic>P</italic> = 0.505).</p><p>Importantly, SLC5A8 expression levels were significantly lower among infected children compared to non-infected with similar conditions of inflammatory activity, lymphoid follicles, and atrophy. Expression was lower for similar levels of gastritis, but differences were not significant (Table <xref ref-type="table" rid="T4">4</xref>).</p><table-wrap id="T4" position="float"><label>Table 4</label><caption><p><bold>mRNA SLC5A8 expression in 11 infected and 9 non-infected children according to levels of histological damage</bold>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" colspan="4" style="border-bottom: thin solid #000000;" rowspan="1"><bold>Median (IQR) of indicated variable by <italic>H. pylori status</italic></bold></th><th rowspan="1" colspan="1"/></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1"><bold>Infected</bold></th><th rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1"><bold>Non-infected</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold><italic>P</italic>-value</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Gastritis</italic></td><td valign="top" align="center" rowspan="1" colspan="1"><italic>(N)</italic></td><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"><italic>(N)</italic></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Normal</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td><td valign="top" align="center" rowspan="1" colspan="1">6</td><td valign="top" align="left" rowspan="1" colspan="1">1.80 (1.21&#x02013;2.19)</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Mild</td><td valign="top" align="center" rowspan="1" colspan="1">5</td><td valign="top" align="left" rowspan="1" colspan="1">0.29 (0.20&#x02013;0.45)</td><td valign="top" align="center" rowspan="1" colspan="1">5</td><td valign="top" align="left" rowspan="1" colspan="1">1.94 (1.06&#x02013;3.74)</td><td valign="top" align="center" rowspan="1" colspan="1">0.34</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Moderate</td><td valign="top" align="center" rowspan="1" colspan="1">4</td><td valign="top" align="left" rowspan="1" colspan="1">0.07 (0,02&#x02013;0.07)</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Severe</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Inflammatory activity</italic></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Presence</td><td valign="top" align="center" rowspan="1" colspan="1">5</td><td valign="top" align="left" rowspan="1" colspan="1">0.10 (0.09&#x02013;0.37)</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Absence</td><td valign="top" align="center" rowspan="1" colspan="1">4</td><td valign="top" align="left" rowspan="1" colspan="1">0.06 (0.02&#x02013;0.10)</td><td valign="top" align="center" rowspan="1" colspan="1">11</td><td valign="top" align="left" rowspan="1" colspan="1">2.00 (0.35&#x02013;3.64)</td><td valign="top" align="center" rowspan="1" colspan="1">0.03</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Lymphoid Follicles</italic></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Presence</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="left" rowspan="1" colspan="1">0.0254 (0.025&#x02013;0.026)</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Absence</td><td valign="top" align="center" rowspan="1" colspan="1">7</td><td valign="top" align="left" rowspan="1" colspan="1">0,20 (0,09&#x02013;0,45)</td><td valign="top" align="center" rowspan="1" colspan="1">11</td><td valign="top" align="left" rowspan="1" colspan="1">1.88 (0.55&#x02013;2.60)</td><td valign="top" align="center" rowspan="1" colspan="1">0.016</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>Atrophy</italic></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Presence</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">1,81</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Absence</td><td valign="top" align="center" rowspan="1" colspan="1">9</td><td valign="top" align="left" rowspan="1" colspan="1">0.10 (0.06&#x02013;0.29)</td><td valign="top" align="center" rowspan="1" colspan="1">10</td><td valign="top" align="left" rowspan="1" colspan="1">1.94 (0.35&#x02013;3.74)</td><td valign="top" align="center" rowspan="1" colspan="1">0.01</td></tr></tbody></table><table-wrap-foot><p><italic>+NS: No subjects in this category</italic>.</p></table-wrap-foot></table-wrap></sec></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>In two separate evaluations, a pilot study and a case-control study, median SLC5A8 expression levels were decreased in blood samples from <italic>H. pylori</italic> infected children less than 6 years of age as compared to non-infected children. This finding was also confirmed in gastric tissue of infected compared to non-infected children. <italic>H. pylori</italic> modulation of gene expression has been demonstrated previously in adult populations (Hanada and Graham, <xref rid="B12" ref-type="bibr">2014</xref>; Obayashi et al., <xref rid="B25" ref-type="bibr">2015</xref>); however, this is the first report of a significant association between SLC5A8 gene expression and <italic>H. pylori</italic> infection in both symptomatic and asymptomatic children.</p><p>The fact that SLC5A8 expression is reduced in fresh whole blood samples (which include several components such as plasma, red blood cells, white blood cells, and platelets) from <italic>H. pylori</italic> infected children raises several hypotheses as to how an infection occurring at the gastric level is affecting the circulatory system. Extracellular vesicles (EVs), which carry mRNAs, noncoding RNA and proteins generated from different biological processes may play a role (EL Andaloussi et al., <xref rid="B5" ref-type="bibr">2013</xref>; Vader et al., <xref rid="B36" ref-type="bibr">2014</xref>). EVs are membrane-enclosed structures that are released into the surrounding environment by nearly all cell types. After separation from the plasma membrane, these vesicles may travel from the extracellular/intracellular space of gastric epithelial cells into the blood stream (Vader et al., <xref rid="B36" ref-type="bibr">2014</xref>). A second hypothesis is that lymphocytes, neutrophils, and macrophages present during an epithelial inflammatory event can be detected in circulating blood (Cadamuro et al., <xref rid="B2" ref-type="bibr">2014</xref>). This would require a peripheral inflammatory environment during chronic <italic>H. pylori</italic> infection, including the presence of macrophages capable of storing genetic information detectable in blood (Fehlings et al., <xref rid="B7" ref-type="bibr">2012</xref>).</p><p>Our findings pose several questions and open several areas for future research. Reduced SLC5A8 expression associated with <italic>H. pylori</italic> infection at such an early age may be sustained over time or may be transitory or fluctuating in association with various factors. There was no correlation between expression levels and a child's age (data not shown). Expectedly, <italic>H. pylori</italic> was associated with more severe gastric tissue damage, and more severe damage (gastritis severity and presence of lymphoid follicles) was associated with decreased SLC5A8 expression levels. Importantly although, in children with similar levels of gastric damage, infection was significantly associated with decreased expression, strongly suggesting that infection is the key player in this effect. Of note is that expression is reduced among infected vs. non-infected children overall, but individually many non-infected children had very low expression levels. Whether infection plays a role in gene expression in only a subset of children, and if these children are possibly at higher risk for cancer occurrence decades later will require long-term cohort monitoring and/or cross-sectional studies in different age groups.</p><p>We did not find an association between SLC5A8 expression levels and the presence of <italic>CagA</italic> among infected individuals. <italic>CagA</italic> amplification in stools is difficult (O'Ryan et al., <xref rid="B24" ref-type="bibr">2013</xref>), and although each sample was tested repeatedly before attributing a positive or negative status, there remains some degree of uncertainty based on the fact that we were attempting to detect a virulence factor present in <italic>H. pylori</italic> at the gastric level in stool samples. Obtaining the <italic>H. pylori</italic> strain directly from the stomach would be ideal, but ethically not feasible for apparently healthy children; unfortunately, there has been little success in culturing this bacteria from stool samples (O'Ryan et al., <xref rid="B24" ref-type="bibr">2013</xref>, <xref rid="B23" ref-type="bibr">2015</xref>). In addition, it is possible that persistent infections may be caused by different strains over time, making our results, based on one sample, inconclusive.</p><p>At this point, it might be interesting to speculate on how reduced SLC5A8 expression in host cells may benefit <italic>H. pylori</italic>. Indeed, this pathogen has been shown to modulate host gene expression in ways that favor host infection (Matsushima et al., <xref rid="B20" ref-type="bibr">2011</xref>; Kim et al., <xref rid="B16" ref-type="bibr">2012</xref>; Hanada and Graham, <xref rid="B12" ref-type="bibr">2014</xref>; O'Ryan et al., <xref rid="B23" ref-type="bibr">2015</xref>; Rossi et al., <xref rid="B30" ref-type="bibr">2016</xref>). As mentioned in this manuscript, SLC5A8 is implicated in the control of short-chain fatty acid uptake, which in turn modulates the expression of cell cycle control and pro-inflammatory genes. Potentially, therefore, one may speculate that loss of SLC5A8 expression induced by <italic>H. pylori</italic> should promote cell proliferation and inflammation, which in turn could favor the infection process and enhance severity of the infection.</p><p>There are limitations to this study. The number of tissue samples analyzed is relatively small and we were not able to analyze blood and tissue from the same children due to lack of dual samples. For healthy children who provided blood samples, it was not ethical to request an endoscopy and tissue biopsy due to their lack of symptoms; for children providing a tissue sample due to symptoms as part of another study, collection of a blood sample was not contemplated at the time of original study design. Histological information was unavailable for 4 children providing gastric biopsy samples, and the standardized Sydney Score was not initially considered, so a less conventional evaluation of gastric damage severity was used. Lastly, we only analyzed one of the genes identified by gene wide array; analysis of additional genes in light of our findings, represent a new challenge.</p><p>Future prospective studies should focus on culturing <italic>H. pylori</italic> strains in both children and adults requiring endoscopy, with different stages of gastric pathology, in order to confirm differences in SLC5A8 expression levels. In addition, longitudinal studies of infected children, including gene expression levels over time, will be required to determine the co-occurrence of persistent infection and decreased gene expression levels. Importantly, studies using <italic>in vitro</italic> models, including different cell lines, will be required to understand the mechanisms involved in reduced gene expression.</p></sec><sec id="s5"><title>Author contributions</title><p>AO conceived, designed, analyzed data, coordinated the study and wrote the manuscript with substantial support from MO, AL, and AQ. SG designed the research experimental studies in stool samples. MO, NM, YL, and JT designed the cohort studies. MM designed the bioinformatics analysis with support from OR and AM. CS and PH designed and performed the clinical studies in children requiring endoscopy, submitting the tissue samples. All authors reviewed and approved the manuscript.</p></sec><sec id="s6"><title>Funding</title><p>This work was supported by the Fondo Nacional de Desarrollo Cient&#x000ed;fico y Tecnol&#x000f3;gico [1061079 and 1100514 to MO, 1130387 to PH, and 11140232 to CS]; Comisi&#x000f3;n Nacional de Investigaci&#x000f3;n Cient&#x000ed;fica y Tecnol&#x000f3;gica [21140520 to AO]; Fondo de Financiamiento de Centros de Investigaci&#x000f3;n en &#x000c1;reas Prioritarias [15130011 to AQ] and Secretar&#x000ed;a de Educaci&#x000f3;n Superior, Ciencia, Tecnolog&#x000ed;a e Innovaci&#x000f3;n [to AO].</p><sec><title>Conflict of interest statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></sec></body><back><ack><p>We thank Elizabeth Cer&#x000f3;n for her dedicated work in the field. The technical assistance of Daniela Fernandois, Natalia Barraza, Jonathan Martinez, and David Montero was important for manuscript structuring. This study was awarded The Prize for Best Oral Presentation at the World Congress of Pediatric Infectious Diseases (WCPID), Brazil, 2015.</p></ack><sec sec-type="supplementary-material" id="s7"><title>Supplementary material</title><p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="http://journal.frontiersin.org/article/10.3389/fcimb.2016.00121">http://journal.frontiersin.org/article/10.3389/fcimb.2016.00121</ext-link></p><supplementary-material content-type="local-data" id="SM1"><media xlink:href="Table1.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brim</surname><given-names>H.</given-names></name><name><surname>Kumar</surname><given-names>K.</given-names></name><name><surname>Nazarian</surname><given-names>J.</given-names></name><name><surname>Hathout</surname><given-names>Y.</given-names></name><name><surname>Jafarian</surname><given-names>A.</given-names></name><name><surname>Lee</surname><given-names>E.</given-names></name><etal/></person-group>. (<year>2011</year>). <article-title>SLC5A8 gene, a transporter of butyrate: a gut flora metabolite, is frequently methylated in African American colon adenomas</article-title>. <source>PLoS ONE</source>
<volume>6</volume>:<fpage>e20216</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0020216</pub-id><?supplied-pmid 21687703?><pub-id pub-id-type="pmid">21687703</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cadamuro</surname><given-names>A. C. T.</given-names></name><name><surname>Rossi</surname><given-names>A. F. T.</given-names></name><name><surname>Maniezzo</surname><given-names>N. M.</given-names></name><name><surname>Silva</surname><given-names>A. E.</given-names></name></person-group> (<year>2014</year>). <article-title><italic>Helicobacter pylori</italic> infection: host immune response, implications on gene expression and microRNAs</article-title>. <source>World J. Gastroenterol.</source>
<volume>20</volume>, <fpage>1424</fpage>&#x02013;<lpage>1437</lpage>. <pub-id pub-id-type="doi">10.3748/wjg.v20.i6.1424</pub-id><?supplied-pmid 24587619?><pub-id pub-id-type="pmid">24587619</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coothankandaswamy</surname><given-names>V.</given-names></name><name><surname>Elangovan</surname><given-names>S.</given-names></name><name><surname>Singh</surname><given-names>N.</given-names></name><name><surname>Prasad</surname><given-names>P. D.</given-names></name><name><surname>Thangaraju</surname><given-names>M.</given-names></name><name><surname>Ganapathy</surname><given-names>V.</given-names></name></person-group> (<year>2013</year>). <article-title>The plasma membrane transporter SLC5A8 suppresses tumour progression through depletion of survivin without involving its transport function</article-title>. <source>Biochem. J.</source>
<volume>450</volume>, <fpage>169</fpage>&#x02013;<lpage>178</lpage>. <pub-id pub-id-type="doi">10.1042/BJ20121248</pub-id><?supplied-pmid 23167260?><pub-id pub-id-type="pmid">23167260</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daugule</surname><given-names>I.</given-names></name><name><surname>Rowland</surname><given-names>M.</given-names></name></person-group> (<year>2008</year>). <article-title><italic>Helicobacter pylori</italic> infection in children</article-title>. <source>Helicobacter</source>
<volume>13</volume>(<issue>Suppl. 1</issue>), <fpage>41</fpage>&#x02013;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1111/j.1523-5378.2008.00632.x</pub-id><?supplied-pmid 23311469?><pub-id pub-id-type="pmid">18783521</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>EL Andaloussi</surname><given-names>S.</given-names></name><name><surname>M&#x000e4;ger</surname><given-names>I.</given-names></name><name><surname>Breakefield</surname><given-names>X. O.</given-names></name><name><surname>Wood</surname><given-names>M. J.</given-names></name></person-group> (<year>2013</year>). <article-title>Extracellular vesicles: biology and emerging therapeutic opportunities</article-title>. <source>Nat. Rev. Drug Discov.</source>
<volume>12</volume>, <fpage>347</fpage>&#x02013;<lpage>357</lpage>. <pub-id pub-id-type="doi">10.1038/nrd3978</pub-id><?supplied-pmid 23584393?><pub-id pub-id-type="pmid">23584393</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elangovan</surname><given-names>S.</given-names></name><name><surname>Pathania</surname><given-names>R.</given-names></name><name><surname>Ramachandran</surname><given-names>S.</given-names></name><name><surname>Ananth</surname><given-names>S.</given-names></name><name><surname>Padia</surname><given-names>R. N.</given-names></name><name><surname>Srinivas</surname><given-names>S. R.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Molecular mechanism of SLC5A8 inactivation in breast cancer</article-title>. <source>Mol. Cell. Biol.</source>
<volume>33</volume>, <fpage>3920</fpage>&#x02013;<lpage>3935</lpage>. <pub-id pub-id-type="doi">10.1128/MCB.01702-12</pub-id><?supplied-pmid 23918800?><pub-id pub-id-type="pmid">23918800</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fehlings</surname><given-names>M.</given-names></name><name><surname>Drobbe</surname><given-names>L.</given-names></name><name><surname>Moos</surname><given-names>V.</given-names></name><name><surname>Renner Viveros</surname><given-names>P.</given-names></name><name><surname>Hagen</surname><given-names>J.</given-names></name><name><surname>Beigier-Bompadre</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2012</year>). <article-title>Comparative analysis of the interaction of Helicobacter pylori with human dendritic cells, macrophages, and monocytes</article-title>. <source>Infect. Immun.</source>
<volume>80</volume>, <fpage>2724</fpage>&#x02013;<lpage>2734</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.00381-12</pub-id><?supplied-pmid 22615251?><pub-id pub-id-type="pmid">22615251</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foglietta</surname><given-names>F.</given-names></name><name><surname>Serpe</surname><given-names>L.</given-names></name><name><surname>Canaparo</surname><given-names>R.</given-names></name><name><surname>Vivenza</surname><given-names>N.</given-names></name><name><surname>Riccio</surname><given-names>G.</given-names></name><name><surname>Imbalzano</surname><given-names>E.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Modulation of butyrate anticancer activity by solid lipid nanoparticle delivery: an <italic>in vitro</italic> investigation on human breast cancer and leukemia cell lines</article-title>. <source>J. Pharm. Pharm. Sci.</source>
<volume>17</volume>, <fpage>231</fpage>&#x02013;<lpage>247</lpage>. <pub-id pub-id-type="doi">10.18433/J3XP4R</pub-id><?supplied-pmid 24934552?><pub-id pub-id-type="pmid">24934552</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganapathy</surname><given-names>V.</given-names></name><name><surname>Gopal</surname><given-names>E.</given-names></name><name><surname>Miyauchi</surname><given-names>S.</given-names></name><name><surname>Prasad</surname><given-names>P. D.</given-names></name></person-group> (<year>2005</year>). <article-title>Biological functions of SLC5A8, a candidate tumour suppressor</article-title>. <source>Biochem. Soc. Trans.</source>
<volume>33</volume>, <fpage>237</fpage>&#x02013;<lpage>240</lpage>. <pub-id pub-id-type="doi">10.1042/BST0330237</pub-id><?supplied-pmid 15667316?><pub-id pub-id-type="pmid">15667316</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganapathy</surname><given-names>V.</given-names></name><name><surname>Thangaraju</surname><given-names>M.</given-names></name><name><surname>Gopal</surname><given-names>E.</given-names></name><name><surname>Martin</surname><given-names>P. M.</given-names></name><name><surname>Itagaki</surname><given-names>S.</given-names></name><name><surname>Miyauchi</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2008</year>). <article-title>Sodium-coupled monocarboxylate transporters in normal tissues and in cancer</article-title>. <source>AAPS J.</source>
<volume>10</volume>, <fpage>193</fpage>&#x02013;<lpage>199</lpage>. <pub-id pub-id-type="doi">10.1208/s12248-008-9022-y</pub-id><?supplied-pmid 18446519?><pub-id pub-id-type="pmid">18446519</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gurav</surname><given-names>A.</given-names></name><name><surname>Sivaprakasam</surname><given-names>S.</given-names></name><name><surname>Bhutia</surname><given-names>Y. D.</given-names></name><name><surname>Boettger</surname><given-names>T.</given-names></name><name><surname>Singh</surname><given-names>N.</given-names></name><name><surname>Ganapathy</surname><given-names>V.</given-names></name></person-group> (<year>2015</year>). <article-title>Slc5a8, a Na + -coupled high-affinity transporter for short-chain fatty acids, is a conditional tumor suppressor in colon that protects against colitis and colon cancer under low-fiber dietary conditions</article-title>. <source>Biochem. J.</source>
<volume>469</volume>, <fpage>267</fpage>&#x02013;<lpage>278</lpage>. <pub-id pub-id-type="doi">10.1042/BJ20150242</pub-id><?supplied-pmid 25984582?><pub-id pub-id-type="pmid">25984582</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanada</surname><given-names>K.</given-names></name><name><surname>Graham</surname><given-names>D. Y.</given-names></name></person-group> (<year>2014</year>). <article-title><italic>Helicobacter pylori</italic> and the molecular pathogenesis of intestinal-type gastric carcinoma</article-title>. <source>Expert Rev. Anticancer Ther.</source>
<volume>14</volume>, <fpage>947</fpage>&#x02013;<lpage>954</lpage>. <pub-id pub-id-type="doi">10.1586/14737140.2014.911092</pub-id><?supplied-pmid 24802804?><pub-id pub-id-type="pmid">24802804</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>D. W.</given-names></name><name><surname>Sherman</surname><given-names>B. T.</given-names></name><name><surname>Lempicki</surname><given-names>R. A.</given-names></name></person-group> (<year>2009</year>). <article-title>Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources</article-title>. <source>Nat. Protoc.</source>
<volume>4</volume>, <fpage>44</fpage>&#x02013;<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1038/nprot.2008.211</pub-id><?supplied-pmid 19131956?><pub-id pub-id-type="pmid">19131956</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaime</surname><given-names>F.</given-names></name><name><surname>Villagr&#x000e1;n</surname><given-names>A.</given-names></name><name><surname>Serrano</surname><given-names>C.</given-names></name><name><surname>Cerda</surname><given-names>J.</given-names></name><name><surname>Harris</surname><given-names>P. R.</given-names></name></person-group> (<year>2013</year>). <article-title>[Frequency of <italic>Helicobacter pylori</italic> infection in 144 school age Chilean children]</article-title>. <source>Rev. Med. Chil.</source>
<volume>141</volume>, <fpage>1249</fpage>&#x02013;<lpage>1254</lpage>. <pub-id pub-id-type="doi">10.4067/S0034-98872013001000003</pub-id><?supplied-pmid 24522352?><pub-id pub-id-type="pmid">24522352</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keenan</surname><given-names>J. I.</given-names></name><name><surname>Frizelle</surname><given-names>F. A.</given-names></name></person-group> (<year>2014</year>). <article-title>Bacteria flying under the radar: linking a bacterial infection to colon carcinogenesis</article-title>. <source>Infect. Agent Cancer</source>
<volume>9</volume>:<fpage>31</fpage>. <pub-id pub-id-type="doi">10.1186/1750-9378-9-31</pub-id><?supplied-pmid 25225573?><pub-id pub-id-type="pmid">25225573</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S. H.</given-names></name><name><surname>Sierra</surname><given-names>R. A</given-names></name><name><surname>McGee</surname><given-names>D. J.</given-names></name><name><surname>Zabaleta</surname><given-names>J.</given-names></name></person-group> (<year>2012</year>). <article-title>Transcriptional profiling of gastric epithelial cells infected with wild type or arginase-deficient Helicobacter pylori</article-title>. <source>BMC Microbiol.</source>
<volume>12</volume>:<fpage>175</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2180-12-175</pub-id><?supplied-pmid 22889111?><pub-id pub-id-type="pmid">22889111</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kr&#x000e4;mer</surname><given-names>A.</given-names></name><name><surname>Green</surname><given-names>J.</given-names></name><name><surname>Pollard</surname><given-names>J.</given-names></name><name><surname>Tugendreich</surname><given-names>S.</given-names></name></person-group> (<year>2014</year>). <article-title>Causal analysis approaches in ingenuity pathway analysis</article-title>. <source>Bioinformatics</source>
<volume>30</volume>, <fpage>523</fpage>&#x02013;<lpage>530</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btt703</pub-id><?supplied-pmid 24336805?><pub-id pub-id-type="pmid">24336805</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Myeroff</surname><given-names>L.</given-names></name><name><surname>Smiraglia</surname><given-names>D.</given-names></name><name><surname>Romero</surname><given-names>M. F.</given-names></name><name><surname>Pretlow</surname><given-names>T. P.</given-names></name><name><surname>Kasturi</surname><given-names>L.</given-names></name><etal/></person-group>. (<year>2003</year>). <article-title>SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>100</volume>, <fpage>8412</fpage>&#x02013;<lpage>8417</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1430846100</pub-id><?supplied-pmid 12829793?><pub-id pub-id-type="pmid">12829793</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malaty</surname><given-names>H. M.</given-names></name></person-group> (<year>2007</year>). <article-title>Epidemiology of Helicobacter pylori infection</article-title>. <source>Best Pract. Res. Clin. Gastroenterol.</source>
<volume>21</volume>, <fpage>205</fpage>&#x02013;<lpage>214</lpage>. <pub-id pub-id-type="doi">10.1016/j.bpg.2006.10.005</pub-id><?supplied-pmid 27531531?><pub-id pub-id-type="pmid">17382273</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsushima</surname><given-names>K.</given-names></name><name><surname>Isomoto</surname><given-names>H.</given-names></name><name><surname>Inoue</surname><given-names>N.</given-names></name><name><surname>Nakayama</surname><given-names>T.</given-names></name><name><surname>Hayashi</surname><given-names>T.</given-names></name><name><surname>Nakayama</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2011</year>). <article-title>MicroRNA signatures in <italic>Helicobacter pylori</italic>-infected gastric mucosa</article-title>. <source>Int. J. Cancer</source>
<volume>128</volume>, <fpage>361</fpage>&#x02013;<lpage>370</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.25348</pub-id><?supplied-pmid 20333682?><pub-id pub-id-type="pmid">20333682</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Minsal</collab></person-group> (<year>2004</year>). <source>Resultados I Encuesta de Salud, Chile 2003. Minist. Salud Gob. Chile</source>. Available online at: <ext-link ext-link-type="uri" xlink:href="http://epi.minsal.cl/epi/html/invest/ENS/InformeFinalENS.pdf">http://epi.minsal.cl/epi/html/invest/ENS/InformeFinalENS.pdf</ext-link>.</mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyauchi</surname><given-names>S.</given-names></name><name><surname>Gopal</surname><given-names>E.</given-names></name><name><surname>Fei</surname><given-names>Y.-J.</given-names></name><name><surname>Ganapathy</surname><given-names>V.</given-names></name></person-group> (<year>2004</year>). <article-title>Functional identification of SLC5A8, a tumor suppressor down-regulated in colon cancer, as a Na(+)-coupled transporter for short-chain fatty acids</article-title>. <source>J. Biol. Chem.</source>
<volume>279</volume>, <fpage>13293</fpage>&#x02013;<lpage>13296</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.C400059200</pub-id><?supplied-pmid 14966140?><pub-id pub-id-type="pmid">14966140</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Ryan</surname><given-names>M. L.</given-names></name><name><surname>Lucero</surname><given-names>Y.</given-names></name><name><surname>Rabello</surname><given-names>M.</given-names></name><name><surname>Mamani</surname><given-names>N.</given-names></name><name><surname>Salinas</surname><given-names>A. M.</given-names></name><name><surname>Pe&#x000f1;a</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>Persistent and transient <italic>Helicobacter pylori</italic> infections in early childhood</article-title>. <source>Clin. Infect. Dis.</source>
<volume>61</volume>, <fpage>211</fpage>&#x02013;<lpage>218</lpage>. <pub-id pub-id-type="doi">10.1093/cid/civ256</pub-id><?supplied-pmid 25838286?><pub-id pub-id-type="pmid">25838286</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Ryan</surname><given-names>M. L.</given-names></name><name><surname>Rabello</surname><given-names>M.</given-names></name><name><surname>Cort&#x000e9;s</surname><given-names>H.</given-names></name><name><surname>Lucero</surname><given-names>Y.</given-names></name><name><surname>Pe&#x000f1;a</surname><given-names>A.</given-names></name><name><surname>Torres</surname><given-names>J. P.</given-names></name></person-group> (<year>2013</year>). <article-title>Dynamics of <italic>Helicobacter pylori</italic> detection in stools during the first 5 years of life in Chile, a rapidly developing country</article-title>. <source>Pediatr. Infect. Dis. J.</source>
<volume>32</volume>, <fpage>99</fpage>&#x02013;<lpage>103</lpage>. <pub-id pub-id-type="doi">10.1097/INF.0b013e318278b929</pub-id><?supplied-pmid 23076385?><pub-id pub-id-type="pmid">23076385</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Obayashi</surname><given-names>N.</given-names></name><name><surname>Ohtsuka</surname><given-names>Y.</given-names></name><name><surname>Hosoi</surname><given-names>K.</given-names></name><name><surname>Ikuse</surname><given-names>T.</given-names></name><name><surname>Jimbo</surname><given-names>K.</given-names></name><name><surname>Aoyagi</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>Comparison of gene expression between pediatric and adult gastric mucosa with <italic>Helicobacter pylori</italic> infection</article-title>. <source>Helicobacter</source>
<volume>21</volume>, <fpage>114</fpage>&#x02013;<lpage>123</lpage>. <pub-id pub-id-type="doi">10.1111/hel.12245</pub-id><?supplied-pmid 26140656?><pub-id pub-id-type="pmid">26140656</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>J. Y.</given-names></name><name><surname>Kim</surname><given-names>D.</given-names></name><name><surname>Yang</surname><given-names>M.</given-names></name><name><surname>Park</surname><given-names>H. Y.</given-names></name><name><surname>Lee</surname><given-names>S. H.</given-names></name><name><surname>Rincon</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Gene silencing of SLC5A8 identified by genome-wide methylation profiling in lung cancer</article-title>. <source>Lung Cancer</source>
<volume>79</volume>, <fpage>198</fpage>&#x02013;<lpage>204</lpage>. <pub-id pub-id-type="doi">10.1016/j.lungcan.2012.11.019</pub-id><?supplied-pmid 23273563?><pub-id pub-id-type="pmid">23273563</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porra</surname><given-names>V.</given-names></name><name><surname>Ferraro-Peyret</surname><given-names>C.</given-names></name><name><surname>Durand</surname><given-names>C.</given-names></name><name><surname>Selmi-Ruby</surname><given-names>S.</given-names></name><name><surname>Giroud</surname><given-names>H.</given-names></name><name><surname>Berger-Dutrieux</surname><given-names>N.</given-names></name><etal/></person-group>. (<year>2005</year>). <article-title>Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas</article-title>. <source>J. Clin. Endocrinol. Metab.</source>
<volume>90</volume>, <fpage>3028</fpage>&#x02013;<lpage>3035</lpage>. <pub-id pub-id-type="doi">10.1210/jc.2004-1394</pub-id><?supplied-pmid 15687339?><pub-id pub-id-type="pmid">15687339</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>X.</given-names></name><name><surname>Huang</surname><given-names>X.</given-names></name><name><surname>Zhou</surname><given-names>Z.</given-names></name><name><surname>Lin</surname><given-names>X.</given-names></name></person-group> (<year>2013</year>). <article-title>An improvement of the 2<sup>(&#x02212;&#x00394;&#x00394;CT)</sup> method for quantitative real-time polymerase chain reaction data analysis</article-title>. <source>Biostat. Bioinforma. Biomath.</source>
<volume>3</volume>, <fpage>71</fpage>&#x02013;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1016/j.biotechadv.2011.08.021</pub-id><?supplied-pmid 25558171?><pub-id pub-id-type="pmid">25558171</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>R Development Core Team</collab></person-group> (<year>2013</year>). <source>R: A Language and Environment for Statistical Computing</source>. <publisher-loc>Vienna</publisher-loc>: <publisher-name>R Foundation for Statistical Computing</publisher-name> Available online at: <ext-link ext-link-type="uri" xlink:href="http://www.R-project.org/">http://www.R-project.org/</ext-link>. R Found. Stat. Comput. <publisher-loc>Vienna, Austria</publisher-loc>.</mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossi</surname><given-names>A. F. T.</given-names></name><name><surname>Cadamuro</surname><given-names>A. C. T.</given-names></name><name><surname>Biselli-P&#x000e9;rico</surname><given-names>J. M.</given-names></name><name><surname>Leite</surname><given-names>K. R. M.</given-names></name><name><surname>Severino</surname><given-names>F. E.</given-names></name><name><surname>Reis</surname><given-names>P. P.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>Interaction between inflammatory mediators and miRNAs in <italic>Helicobacter pylori</italic> infection</article-title>. <source>Cell. Microbiol</source>. <volume>18</volume>, <fpage>1444</fpage>&#x02013;<lpage>1458</lpage>. <pub-id pub-id-type="doi">10.1111/cmi.12587</pub-id><?supplied-pmid 26945693?><pub-id pub-id-type="pmid">26945693</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schagdarsurengin</surname><given-names>U.</given-names></name><name><surname>Gimm</surname><given-names>O.</given-names></name><name><surname>Dralle</surname><given-names>H.</given-names></name><name><surname>Hoang-Vu</surname><given-names>C.</given-names></name><name><surname>Dammann</surname><given-names>R.</given-names></name></person-group> (<year>2006</year>). <article-title>CpG island methylation of tumor-related promoters occurs preferentially in undifferentiated carcinoma</article-title>. <source>Thyroid</source>
<volume>16</volume>, <fpage>633</fpage>&#x02013;<lpage>642</lpage>. <pub-id pub-id-type="doi">10.1089/thy.2006.16.633</pub-id><?supplied-pmid 16889486?><pub-id pub-id-type="pmid">16889486</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thangaraju</surname><given-names>M.</given-names></name><name><surname>Cresci</surname><given-names>G.</given-names></name><name><surname>Itagaki</surname><given-names>S.</given-names></name><name><surname>Mellinger</surname><given-names>J.</given-names></name><name><surname>Browning</surname><given-names>D. D.</given-names></name><name><surname>Berger</surname><given-names>F. G.</given-names></name><etal/></person-group>. (<year>2008</year>). <article-title>Sodium-coupled transport of the short chain fatty acid butyrate by SLC5A8 and its relevance to colon cancer</article-title>. <source>J. Gastrointest. Surg.</source>
<volume>12</volume>, <fpage>1773</fpage>&#x02013;<lpage>1781</lpage>. discussion: 1781&#x02013;1782. <pub-id pub-id-type="doi">10.1007/s11605-008-0573-0</pub-id><?supplied-pmid 18661192?><pub-id pub-id-type="pmid">18661192</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thangaraju</surname><given-names>M.</given-names></name><name><surname>Gopal</surname><given-names>E.</given-names></name><name><surname>Martin</surname><given-names>P. M.</given-names></name><name><surname>Ananth</surname><given-names>S.</given-names></name><name><surname>Smith</surname><given-names>S. B.</given-names></name><name><surname>Prasad</surname><given-names>P. D.</given-names></name><etal/></person-group>. (<year>2006</year>). <article-title>SLC5A8 triggers tumor cell apoptosis through pyruvate-dependent inhibition of histone deacetylases</article-title>. <source>Cancer Res.</source>
<volume>66</volume>, <fpage>11560</fpage>&#x02013;<lpage>11564</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-1950</pub-id><?supplied-pmid 17178845?><pub-id pub-id-type="pmid">17178845</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thangaraju</surname><given-names>M.</given-names></name><name><surname>Karunakaran</surname><given-names>S. K.</given-names></name><name><surname>Itagaki</surname><given-names>S.</given-names></name><name><surname>Gopal</surname><given-names>E.</given-names></name><name><surname>Elangovan</surname><given-names>S.</given-names></name><name><surname>Prasad</surname><given-names>P. D.</given-names></name><etal/></person-group>. (<year>2009</year>). <article-title>Transport by SLC5A8 with subsequent inhibition of histone deacetylase 1 (HDAC1) and HDAC3 underlies the antitumor activity of 3-bromopyruvate</article-title>. <source>Cancer</source>
<volume>115</volume>, <fpage>4655</fpage>&#x02013;<lpage>4666</lpage>. <pub-id pub-id-type="doi">10.1002/cncr.24532</pub-id><?supplied-pmid 19637353?><pub-id pub-id-type="pmid">19637353</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ueno</surname><given-names>M.</given-names></name><name><surname>Toyota</surname><given-names>M.</given-names></name><name><surname>Akino</surname><given-names>K.</given-names></name><name><surname>Suzuki</surname><given-names>H.</given-names></name><name><surname>Kusano</surname><given-names>M.</given-names></name><name><surname>Satoh</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2004</year>). <article-title>Aberrant methylation and histone deacetylation associated with silencing of SLC5A8 in gastric cancer</article-title>. <source>Tumour Biol.</source>
<volume>25</volume>, <fpage>134</fpage>&#x02013;<lpage>140</lpage>. <pub-id pub-id-type="doi">10.1159/000079145</pub-id><?supplied-pmid 15361710?><pub-id pub-id-type="pmid">15361710</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vader</surname><given-names>P.</given-names></name><name><surname>Breakefield</surname><given-names>X. O.</given-names></name><name><surname>Wood</surname><given-names>M. J. A.</given-names></name></person-group> (<year>2014</year>). <article-title>Extracellular vesicles: emerging targets for cancer therapy</article-title>. <source>Trends Mol. Med.</source>
<volume>20</volume>, <fpage>385</fpage>&#x02013;<lpage>393</lpage>. <pub-id pub-id-type="doi">10.1016/j.molmed.2014.03.002</pub-id><?supplied-pmid 24703619?><pub-id pub-id-type="pmid">24703619</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Bao</surname><given-names>Y.-L.</given-names></name><name><surname>Yang</surname><given-names>M.-T.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Yu</surname><given-names>C.-L.</given-names></name><name><surname>Huang</surname><given-names>Y.-X.</given-names></name><etal/></person-group>. (<year>2010</year>). <article-title>Activin A induces SLC5A8 expression through the Smad3 signaling pathway in human colon cancer RKO cells</article-title>. <source>Int. J. Biochem. Cell Biol.</source>
<volume>42</volume>, <fpage>1964</fpage>&#x02013;<lpage>1972</lpage>. <pub-id pub-id-type="doi">10.1016/j.biocel.2010.08.007</pub-id><?supplied-pmid 20732443?><pub-id pub-id-type="pmid">20732443</pub-id></mixed-citation></ref></ref-list></back></article>